VELCADE,Rituximab,Cyclophosphamide and Decadron

Phase II Study Investigating the Efficacy of VELCADE®, Rituximab, Cyclophosphamide and Decadron (VRCD Regimen) in Front-line Therapy of Patients With Low-grade Non-Hodgkin's Lymphoma

Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma.

This is a phase II open label study that is looking at the VRCD combination regimen in patients with previously untreated low-grade Non-Hodgkin's Lymphoma. Treatment will start by combining oral dexamethasone and cyclophosphamide with intravenous VELCADE, rituximab. Chemotherapy cycles will be given as outlined below every 35-days and will continue until two cycles beyond complete remission (CR), toxicity, patient's withdrawal, disease progression, or a maximum of 8 cycles.

Inclusion Criteria:

• Small Lymphocytic Lymphoma
• Follicular Cell Lymphoma (grades I and II)
• Mantle Cell Lymphoma patients that are not considered eligible for high-dose therapy and stem cell transplant
• Lymphoplasmacytic lymphoma including Waldenstrom's Macroglobulinemia
• Marginal Zone Lymphoma
• MALT Lymphoma that has ONLY failed antibiotic therapy or involved field radiation.
• Adequate bone marrow function, renal function, and hepatic function as outlined in details below.
• ECOG performance status of 0, 1, or 2
• Able to read, understand, and sign an IRB approved informed consent

Exclusion Criteria:

• Known HIV positive status
• Known CNS involvement
• Prior therapy for lymphoma EXCLUDING antibiotic treatment for MALT-Type NHL.